<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01584609</url>
  </required_header>
  <id_info>
    <org_study_id>CLP 4853</org_study_id>
    <secondary_id>CLP 4853</secondary_id>
    <nct_id>NCT01584609</nct_id>
  </id_info>
  <brief_title>A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke</brief_title>
  <official_title>A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penumbra Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Penumbra Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, single blind, concurrent controlled, multi-center study.
      Patients presenting with symptoms of acute ischemic stroke who have evidence of a large
      vessel (2.5mm or greater in diameter) occlusion in the cerebral circulation will be assigned
      to either the Penumbra System with the Separator 3D or the Penumbra System without the
      Separator 3D. Each treated patient will be followed and assessed for 3 months after
      randomization. Up to 230 evaluable patients at up to 50 centers presenting with acute
      ischemic stroke in vessels accessible to the Penumbra Separator 3D System for
      revascularization within 8 hours of symptom onset. The hypothesis to be tested is that the
      safety and effectiveness of the Penumbra System with the Separator 3D for the
      revascularization of large vessel occlusion is not inferior to the Penumbra System alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Angiographic Revascularization of the Occluded Target Vessel</measure>
    <time_frame>At immediate post-procedure</time_frame>
    <description>Number of Participants with Angiographic revascularization of the occluded target vessel defined by mTICI grade 2-3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Device-related Serious Adverse Events</measure>
    <time_frame>Within 24 hours post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Procedure-related Serious Adverse Event</measure>
    <time_frame>Within 24 hours post-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Good Clinical Outcome at 30 Days</measure>
    <time_frame>30 days post-procedure</time_frame>
    <description>Defined by a 10 points or more improvement in the NIHSS at Discharge, a NIHSS score of 0-1 at Discharge; or a 30-day mRS score of 0-2. The NIHSS is a stroke scale that measures impairment caused by stroke. The Modified Rankin scale (mRS) measures neurological disability or dependence for stroke patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With 90 Day mRS Score 0-2</measure>
    <time_frame>at 90 days post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>At 90 days post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Symptomatic Intracranial Hemorrhage</measure>
    <time_frame>Within 24 hours post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good Neurological Outcome at 90 Days</measure>
    <time_frame>At 90 days post-procedure</time_frame>
    <description>Defined by an mRS score of 0-2, or equal to the pre-stroke mRS score if the pre-stroke mRS score was higher than 2, or an improvement of 10 or more points on the NIHSS score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">198</enrollment>
  <condition>Acute Ischemic Stroke From Large Vessel Occlusion</condition>
  <arm_group>
    <arm_group_label>Penumbra System with Separator 3D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Penumbra System alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Penumbra System with Separator 3D</intervention_name>
    <description>The Separator 3D is an additional Separator with a new tip configuration for the Penumbra System.</description>
    <arm_group_label>Penumbra System with Separator 3D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Penumbra System alone</intervention_name>
    <description>The Penumbra SystemÂ® is a new generation of neuro-embolectomy devices specifically designed to remove thrombus through aspiration.The treatment paradigm of this System involves the introduction of the Reperfusion Catheter through a guide catheter into the intracranial vasculature, and guided over an appropriate guidewire to the site of primary occlusion. The Reperfusion Catheter is used in parallel with the Separator and an aspiration source (Aspiration Pump) to separate the thrombus and aspirate it from the occluded vessel.</description>
    <arm_group_label>Penumbra System alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  From 18 to 85 years of age

          -  Present with symptoms consistent with an acute ischemic stroke for revascularization
             within 8 hours from symptom onset

          -  Refractory to or not eligible for IV rtPA therapy., e.g., presenting between 0 and 3
             hours from symptom onset AND contraindicated for IV rtPA, or presenting between 3 and
             8 hours of symptom onset, or evidence of persistent occlusion from vascular imaging
             after IV rtPA

          -  Evidence of a large vessel (2.5mm or greater in diameter) occlusion in the cerebral
             circulation

          -  NIH Stroke Scale (NIHSS) score 8 or more points

          -  Signed informed consent

        Exclusion Criteria:

          -  History of stroke in the past 3 months.

          -  Females who are pregnant

          -  Pre-existing neurological or psychiatric disease that could confound the study results
             such as a pre-stroke mRS score 1 or higher

          -  Known severe allergy to contrast media

          -  Uncontrolled hypertension (defined as systolic blood pressure &gt;185 mmHg or diastolic
             blood pressure &gt;110 mmHg)

          -  CT evidence of the following conditions at randomization:

               -  Significant mass effect with midline shift

               -  Large infarct region &gt;1/3 of the middle cerebral artery territory

               -  Evidence of intracranial hemorrhage

          -  Angiographic evidence of an arterial stenosis proximal to the occlusion that could
             prevent thrombus removal

          -  Angiographic evidence of preexisting arterial injury

          -  Rapidly improving neurological status prior to enrollment

          -  Bilateral stroke

          -  Intracranial tumors

          -  Known history of cerebral aneurysm or arteriovenous malformation

          -  Known hemorrhagic diathesis, coagulation deficiency, or on anticoagulant therapy with
             an International Normalized Ratio (INR) of &gt;1.7

          -  Baseline platelets &lt;50,000

          -  Use of IV heparin in the past 48 hours with PTT &gt;1.5 times the normalized ratio

          -  Baseline glucose &lt;50mg/dL or &gt;300mg/dL

          -  Life expectancy less than 90 days prior to stroke onset

          -  Participation in another clinical investigation that could confound the evaluation of
             the study device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Frei, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swedish Medical Center, Denver, CO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hoag Hospital</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>6106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grady Health System</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital- Healtheast</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaleida Health</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-8122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>April 23, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2012</study_first_posted>
  <results_first_submitted>May 17, 2018</results_first_submitted>
  <results_first_submitted_qc>September 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 13, 2018</results_first_posted>
  <last_update_submitted>September 11, 2018</last_update_submitted>
  <last_update_submitted_qc>September 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemic stroke</keyword>
  <keyword>large vessel occlusion</keyword>
  <keyword>mechanical thrombectomy</keyword>
  <keyword>revascularization</keyword>
  <keyword>Penumbra System</keyword>
  <keyword>Separator 3D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 27, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT01584609/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 5, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT01584609/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Penumbra System With Separator 3D</title>
          <description>Penumbra System with Separator 3D: The Separator 3D is an additional Separator with a new tip configuration for the Penumbra System.</description>
        </group>
        <group group_id="P2">
          <title>Penumbra System Alone</title>
          <description>Penumbra System alone: The Penumbra SystemÂ® is a new generation of neuro-embolectomy devices specifically designed to remove thrombus through aspiration.The treatment paradigm of this System involves the introduction of the Reperfusion Catheter through a guide catheter into the intracranial vasculature, and guided over an appropriate guidewire to the site of primary occlusion. The Reperfusion Catheter is used in parallel with the Separator and an aspiration source (Aspiration Pump) to separate the thrombus and aspirate it from the occluded vessel.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Penumbra System With Separator 3D</title>
          <description>Penumbra System with Separator 3D: The Separator 3D is an additional Separator with a new tip configuration for the Penumbra System.</description>
        </group>
        <group group_id="B2">
          <title>Penumbra System Alone</title>
          <description>Penumbra System alone: The Penumbra SystemÂ® is a new generation of neuro-embolectomy devices specifically designed to remove thrombus through aspiration.The treatment paradigm of this System involves the introduction of the Reperfusion Catheter through a guide catheter into the intracranial vasculature, and guided over an appropriate guidewire to the site of primary occlusion. The Reperfusion Catheter is used in parallel with the Separator and an aspiration source (Aspiration Pump) to separate the thrombus and aspirate it from the occluded vessel.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="198"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="100"/>
                    <count group_id="B3" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.3" spread="13.6"/>
                    <measurement group_id="B2" value="66.5" spread="12.5"/>
                    <measurement group_id="B3" value="66.9" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="100"/>
                    <count group_id="B3" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                    <count group_id="B2" value="100"/>
                    <count group_id="B3" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Angiographic Revascularization of the Occluded Target Vessel</title>
        <description>Number of Participants with Angiographic revascularization of the occluded target vessel defined by mTICI grade 2-3</description>
        <time_frame>At immediate post-procedure</time_frame>
        <population>Analysis population demonstrate outcomes of number of subjects that met endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Penumbra System With Separator 3D</title>
            <description>Penumbra System with Separator 3D: The Separator 3D is an additional Separator with a new tip configuration for the Penumbra System.</description>
          </group>
          <group group_id="O2">
            <title>Penumbra System Alone</title>
            <description>Penumbra System alone: The Penumbra SystemÂ® is a new generation of neuro-embolectomy devices specifically designed to remove thrombus through aspiration.The treatment paradigm of this System involves the introduction of the Reperfusion Catheter through a guide catheter into the intracranial vasculature, and guided over an appropriate guidewire to the site of primary occlusion. The Reperfusion Catheter is used in parallel with the Separator and an aspiration source (Aspiration Pump) to separate the thrombus and aspirate it from the occluded vessel.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Angiographic Revascularization of the Occluded Target Vessel</title>
          <description>Number of Participants with Angiographic revascularization of the occluded target vessel defined by mTICI grade 2-3</description>
          <population>Analysis population demonstrate outcomes of number of subjects that met endpoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Device-related Serious Adverse Events</title>
        <time_frame>Within 24 hours post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Penumbra System With Separator 3D</title>
            <description>Penumbra System with Separator 3D: The Separator 3D is an additional Separator with a new tip configuration for the Penumbra System.</description>
          </group>
          <group group_id="O2">
            <title>Penumbra System Alone</title>
            <description>Penumbra System alone: The Penumbra SystemÂ® is a new generation of neuro-embolectomy devices specifically designed to remove thrombus through aspiration.The treatment paradigm of this System involves the introduction of the Reperfusion Catheter through a guide catheter into the intracranial vasculature, and guided over an appropriate guidewire to the site of primary occlusion. The Reperfusion Catheter is used in parallel with the Separator and an aspiration source (Aspiration Pump) to separate the thrombus and aspirate it from the occluded vessel.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Device-related Serious Adverse Events</title>
          <units>Device-Related Serious Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Procedure-related Serious Adverse Event</title>
        <time_frame>Within 24 hours post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Penumbra System With Separator 3D</title>
            <description>Penumbra System with Separator 3D: The Separator 3D is an additional Separator with a new tip configuration for the Penumbra System.</description>
          </group>
          <group group_id="O2">
            <title>Penumbra System Alone</title>
            <description>Penumbra System alone: The Penumbra SystemÂ® is a new generation of neuro-embolectomy devices specifically designed to remove thrombus through aspiration.The treatment paradigm of this System involves the introduction of the Reperfusion Catheter through a guide catheter into the intracranial vasculature, and guided over an appropriate guidewire to the site of primary occlusion. The Reperfusion Catheter is used in parallel with the Separator and an aspiration source (Aspiration Pump) to separate the thrombus and aspirate it from the occluded vessel.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Procedure-related Serious Adverse Event</title>
          <units>Procedure-related Serious Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Good Clinical Outcome at 30 Days</title>
        <description>Defined by a 10 points or more improvement in the NIHSS at Discharge, a NIHSS score of 0-1 at Discharge; or a 30-day mRS score of 0-2. The NIHSS is a stroke scale that measures impairment caused by stroke. The Modified Rankin scale (mRS) measures neurological disability or dependence for stroke patients.</description>
        <time_frame>30 days post-procedure</time_frame>
        <population>Analysis population demonstrate outcomes of number of subjects that met endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Penumbra System With Separator 3D</title>
            <description>Penumbra System with Separator 3D: The Separator 3D is an additional Separator with a new tip configuration for the Penumbra System.</description>
          </group>
          <group group_id="O2">
            <title>Penumbra System Alone</title>
            <description>Penumbra System alone: The Penumbra SystemÂ® is a new generation of neuro-embolectomy devices specifically designed to remove thrombus through aspiration.The treatment paradigm of this System involves the introduction of the Reperfusion Catheter through a guide catheter into the intracranial vasculature, and guided over an appropriate guidewire to the site of primary occlusion. The Reperfusion Catheter is used in parallel with the Separator and an aspiration source (Aspiration Pump) to separate the thrombus and aspirate it from the occluded vessel.</description>
          </group>
        </group_list>
        <measure>
          <title>Good Clinical Outcome at 30 Days</title>
          <description>Defined by a 10 points or more improvement in the NIHSS at Discharge, a NIHSS score of 0-1 at Discharge; or a 30-day mRS score of 0-2. The NIHSS is a stroke scale that measures impairment caused by stroke. The Modified Rankin scale (mRS) measures neurological disability or dependence for stroke patients.</description>
          <population>Analysis population demonstrate outcomes of number of subjects that met endpoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With 90 Day mRS Score 0-2</title>
        <time_frame>at 90 days post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Penumbra System With Separator 3D</title>
            <description>Penumbra System with Separator 3D: The Separator 3D is an additional Separator with a new tip configuration for the Penumbra System.</description>
          </group>
          <group group_id="O2">
            <title>Penumbra System Alone</title>
            <description>Penumbra System alone: The Penumbra SystemÂ® is a new generation of neuro-embolectomy devices specifically designed to remove thrombus through aspiration.The treatment paradigm of this System involves the introduction of the Reperfusion Catheter through a guide catheter into the intracranial vasculature, and guided over an appropriate guidewire to the site of primary occlusion. The Reperfusion Catheter is used in parallel with the Separator and an aspiration source (Aspiration Pump) to separate the thrombus and aspirate it from the occluded vessel.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 90 Day mRS Score 0-2</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality</title>
        <time_frame>At 90 days post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Penumbra System With Separator 3D</title>
            <description>Penumbra System with Separator 3D: The Separator 3D is an additional Separator with a new tip configuration for the Penumbra System.</description>
          </group>
          <group group_id="O2">
            <title>Penumbra System Alone</title>
            <description>Penumbra System alone: The Penumbra SystemÂ® is a new generation of neuro-embolectomy devices specifically designed to remove thrombus through aspiration.The treatment paradigm of this System involves the introduction of the Reperfusion Catheter through a guide catheter into the intracranial vasculature, and guided over an appropriate guidewire to the site of primary occlusion. The Reperfusion Catheter is used in parallel with the Separator and an aspiration source (Aspiration Pump) to separate the thrombus and aspirate it from the occluded vessel.</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Symptomatic Intracranial Hemorrhage</title>
        <time_frame>Within 24 hours post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Penumbra System With Separator 3D</title>
            <description>Penumbra System with Separator 3D: The Separator 3D is an additional Separator with a new tip configuration for the Penumbra System.</description>
          </group>
          <group group_id="O2">
            <title>Penumbra System Alone</title>
            <description>Penumbra System alone: The Penumbra SystemÂ® is a new generation of neuro-embolectomy devices specifically designed to remove thrombus through aspiration.The treatment paradigm of this System involves the introduction of the Reperfusion Catheter through a guide catheter into the intracranial vasculature, and guided over an appropriate guidewire to the site of primary occlusion. The Reperfusion Catheter is used in parallel with the Separator and an aspiration source (Aspiration Pump) to separate the thrombus and aspirate it from the occluded vessel.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Symptomatic Intracranial Hemorrhage</title>
          <units>Symptomatic Intracranial Hemorrhage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Good Neurological Outcome at 90 Days</title>
        <description>Defined by an mRS score of 0-2, or equal to the pre-stroke mRS score if the pre-stroke mRS score was higher than 2, or an improvement of 10 or more points on the NIHSS score</description>
        <time_frame>At 90 days post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Penumbra System With Separator 3D</title>
            <description>Penumbra System with Separator 3D: The Separator 3D is an additional Separator with a new tip configuration for the Penumbra System.</description>
          </group>
          <group group_id="O2">
            <title>Penumbra System Alone</title>
            <description>Penumbra System alone: The Penumbra SystemÂ® is a new generation of neuro-embolectomy devices specifically designed to remove thrombus through aspiration.The treatment paradigm of this System involves the introduction of the Reperfusion Catheter through a guide catheter into the intracranial vasculature, and guided over an appropriate guidewire to the site of primary occlusion. The Reperfusion Catheter is used in parallel with the Separator and an aspiration source (Aspiration Pump) to separate the thrombus and aspirate it from the occluded vessel.</description>
          </group>
        </group_list>
        <measure>
          <title>Good Neurological Outcome at 90 Days</title>
          <description>Defined by an mRS score of 0-2, or equal to the pre-stroke mRS score if the pre-stroke mRS score was higher than 2, or an improvement of 10 or more points on the NIHSS score</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Procedure up to 90 days</time_frame>
      <desc>Serious Adverse Events and Other (Not Including Serious): the total number of subjects analyzed is per protocol population. Data includes roll-in subjects and adjudicated by CEC. Events labeled as is in our Instructions for Use.</desc>
      <group_list>
        <group group_id="E1">
          <title>Penumbra System With Separator 3D</title>
          <description>Penumbra System with Separator 3D: The Separator 3D is an additional Separator with a new tip configuration for the Penumbra System.</description>
        </group>
        <group group_id="E2">
          <title>Penumbra System Alone</title>
          <description>Penumbra System alone: The Penumbra SystemÂ® is a new generation of neuro-embolectomy devices specifically designed to remove thrombus through aspiration.The treatment paradigm of this System involves the introduction of the Reperfusion Catheter through a guide catheter into the intracranial vasculature, and guided over an appropriate guidewire to the site of primary occlusion. The Reperfusion Catheter is used in parallel with the Separator and an aspiration source (Aspiration Pump) to separate the thrombus and aspirate it from the occluded vessel.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="88"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="88"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic, and mediastinal disorders</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="88"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Disorders</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="88"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Disorders</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="88"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="88"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and Infestations</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="88"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="88"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="88"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="88"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous System Disorders</sub_title>
                <counts group_id="E1" events="48" subjects_affected="48" subjects_at_risk="88"/>
                <counts group_id="E2" events="59" subjects_affected="59" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="88"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="88"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic, and mediastinal disorders</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="88"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="88"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Disorder</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="88"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michaella Corso</name_or_title>
      <organization>Penumbra, Inc.</organization>
      <phone>(510) 748-3200</phone>
      <email>mcorso@penumbrainc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

